Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

How Roche Tweaked an Aging Drug to Keep Profits Rolling In

Discussion in 'Other Health News and Research' started by Murph, Sep 6, 2017.

  1. Murph

    Murph :)

    Messages:
    505
    Likes:
    2,605
    https://www.bloomberg.com/news/arti...al&utm_source=twitter.com&utm_campaign=buffer

    In the remote forests of northern Sweden, Anders Svenningsson’s multiple sclerosis patients have benefited from a drug he’s been prescribing for the past eight years. It doesn’t require weekly injections, doesn’t leave patients feeling achy and feverish; and most important, halts their disease.

    That drug, Rituxan—originally developed to treat cancer—has become Sweden’s most prescribed medicine for MS, in which the body attacks its own central nervous system. Swedish doctors have great freedom to prescribe treatments they believe are appropriate, but few MS patients elsewhere can get the drug. That’s because its maker, Roche Holding AG, has never tried to sell it for the disease. Instead, Roche this year introduced a nearly identical medication that it markets under a new name and at 10 times the cost.
     
  2. hixxy

    hixxy Senior Member

    Messages:
    1,121
    Likes:
    1,294
    Australia
    When will this bullshit end?
     

See more popular forum discussions.

Share This Page